BDBM305367 US10144734, Example 384::US10172845, Example 384::US10441581, Example 384::US10881652, Example 384

SMILES: CCOc1cc(-c2ccc(nc2)N2CCC(CN(C)C)(CC2)NC(=O)c2ncccc2Cl)c2c(cnn2c1)C#N

InChI Key: InChIKey=IYKHJTZGKNJOLA-UHFFFAOYSA-N

Data: 12 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 305367   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Proto-oncogene tyrosine-protein kinase receptor Ret (Homo sapiens (Human))	BDBM305367 (US10144734, Example 384 | US10172845, Example 384 ...) Show SMILES CCOc1cc(-c2ccc(nc2)N2CCC(CN(C)C)(CC2)NC(=O)c2ncccc2Cl)c2c(cnn2c1)C#N Show InChI InChI=1S/C29H31ClN8O2/c1-4-40-22-14-23(27-21(15-31)17-34-38(27)18-22)20-7-8-25(33-16-20)37-12-9-29(10-13-37,19-36(2)3)35-28(39)26-24(30)6-5-11-32-26/h5-8,11,14,16-18H,4,9-10,12-13,19H2,1-3H3,(H,35,39)	PDB MMDB KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	5.70	n/a	n/a	n/a	n/a	n/a	n/a
Array BioPharma Inc. US Patent					Assay Description Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...				US Patent US10144734 (2018) BindingDB Entry DOI: 10.7270/Q2251M8C
					More data for this Ligand-Target Pair
RET kinase mutant (V804M) (Homo sapiens (Human))	BDBM305367 (US10144734, Example 384 | US10172845, Example 384 ...) Show SMILES CCOc1cc(-c2ccc(nc2)N2CCC(CN(C)C)(CC2)NC(=O)c2ncccc2Cl)c2c(cnn2c1)C#N Show InChI InChI=1S/C29H31ClN8O2/c1-4-40-22-14-23(27-21(15-31)17-34-38(27)18-22)20-7-8-25(33-16-20)37-12-9-29(10-13-37,19-36(2)3)35-28(39)26-24(30)6-5-11-32-26/h5-8,11,14,16-18H,4,9-10,12-13,19H2,1-3H3,(H,35,39)	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
Array BioPharma Inc. US Patent					Assay Description Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...				US Patent US10144734 (2018) BindingDB Entry DOI: 10.7270/Q2251M8C
					More data for this Ligand-Target Pair
RET kinase mutant (G810R) (Homo sapiens (Human))	BDBM305367 (US10144734, Example 384 | US10172845, Example 384 ...) Show SMILES CCOc1cc(-c2ccc(nc2)N2CCC(CN(C)C)(CC2)NC(=O)c2ncccc2Cl)c2c(cnn2c1)C#N Show InChI InChI=1S/C29H31ClN8O2/c1-4-40-22-14-23(27-21(15-31)17-34-38(27)18-22)20-7-8-25(33-16-20)37-12-9-29(10-13-37,19-36(2)3)35-28(39)26-24(30)6-5-11-32-26/h5-8,11,14,16-18H,4,9-10,12-13,19H2,1-3H3,(H,35,39)	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	22	n/a	n/a	n/a	n/a	n/a	n/a
Array BioPharma Inc. US Patent					Assay Description The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...				US Patent US10144734 (2018) BindingDB Entry DOI: 10.7270/Q2251M8C
					More data for this Ligand-Target Pair
RET Kinase (aa 658-1114) (Homo sapiens (Human))	BDBM305367 (US10144734, Example 384 | US10172845, Example 384 ...) Show SMILES CCOc1cc(-c2ccc(nc2)N2CCC(CN(C)C)(CC2)NC(=O)c2ncccc2Cl)c2c(cnn2c1)C#N Show InChI InChI=1S/C29H31ClN8O2/c1-4-40-22-14-23(27-21(15-31)17-34-38(27)18-22)20-7-8-25(33-16-20)37-12-9-29(10-13-37,19-36(2)3)35-28(39)26-24(30)6-5-11-32-26/h5-8,11,14,16-18H,4,9-10,12-13,19H2,1-3H3,(H,35,39)	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	5.70	n/a	n/a	n/a	n/a	n/a	n/a
Array BioPharma Inc. US Patent					Assay Description Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...				US Patent US10172845 (2019) BindingDB Entry DOI: 10.7270/Q2M90BR9
					More data for this Ligand-Target Pair
RET Kinase (V804M) (aa658-end) (Homo sapiens (Human))	BDBM305367 (US10144734, Example 384 | US10172845, Example 384 ...) Show SMILES CCOc1cc(-c2ccc(nc2)N2CCC(CN(C)C)(CC2)NC(=O)c2ncccc2Cl)c2c(cnn2c1)C#N Show InChI InChI=1S/C29H31ClN8O2/c1-4-40-22-14-23(27-21(15-31)17-34-38(27)18-22)20-7-8-25(33-16-20)37-12-9-29(10-13-37,19-36(2)3)35-28(39)26-24(30)6-5-11-32-26/h5-8,11,14,16-18H,4,9-10,12-13,19H2,1-3H3,(H,35,39)	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
Array BioPharma Inc. US Patent					Assay Description Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...				US Patent US10172845 (2019) BindingDB Entry DOI: 10.7270/Q2M90BR9
					More data for this Ligand-Target Pair
RET kinase mutant (G810R) (Homo sapiens (Human))	BDBM305367 (US10144734, Example 384 | US10172845, Example 384 ...) Show SMILES CCOc1cc(-c2ccc(nc2)N2CCC(CN(C)C)(CC2)NC(=O)c2ncccc2Cl)c2c(cnn2c1)C#N Show InChI InChI=1S/C29H31ClN8O2/c1-4-40-22-14-23(27-21(15-31)17-34-38(27)18-22)20-7-8-25(33-16-20)37-12-9-29(10-13-37,19-36(2)3)35-28(39)26-24(30)6-5-11-32-26/h5-8,11,14,16-18H,4,9-10,12-13,19H2,1-3H3,(H,35,39)	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	22	n/a	n/a	n/a	n/a	n/a	n/a
Array Biopharma Inc. US Patent					Assay Description The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...				US Patent US10881652 (2021)
					More data for this Ligand-Target Pair
RET Kinase (V804M) (aa658-end) (Homo sapiens (Human))	BDBM305367 (US10144734, Example 384 | US10172845, Example 384 ...) Show SMILES CCOc1cc(-c2ccc(nc2)N2CCC(CN(C)C)(CC2)NC(=O)c2ncccc2Cl)c2c(cnn2c1)C#N Show InChI InChI=1S/C29H31ClN8O2/c1-4-40-22-14-23(27-21(15-31)17-34-38(27)18-22)20-7-8-25(33-16-20)37-12-9-29(10-13-37,19-36(2)3)35-28(39)26-24(30)6-5-11-32-26/h5-8,11,14,16-18H,4,9-10,12-13,19H2,1-3H3,(H,35,39)	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	5.70	n/a	n/a	n/a	n/a	n/a	n/a
Array Biopharma Inc. US Patent					Assay Description Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...				US Patent US10441581 (2019) BindingDB Entry DOI: 10.7270/Q2DZ0BP3
					More data for this Ligand-Target Pair
RET kinase mutant (G810R) (Homo sapiens (Human))	BDBM305367 (US10144734, Example 384 | US10172845, Example 384 ...) Show SMILES CCOc1cc(-c2ccc(nc2)N2CCC(CN(C)C)(CC2)NC(=O)c2ncccc2Cl)c2c(cnn2c1)C#N Show InChI InChI=1S/C29H31ClN8O2/c1-4-40-22-14-23(27-21(15-31)17-34-38(27)18-22)20-7-8-25(33-16-20)37-12-9-29(10-13-37,19-36(2)3)35-28(39)26-24(30)6-5-11-32-26/h5-8,11,14,16-18H,4,9-10,12-13,19H2,1-3H3,(H,35,39)	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
Array Biopharma Inc. US Patent					Assay Description The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...				US Patent US10441581 (2019) BindingDB Entry DOI: 10.7270/Q2DZ0BP3
					More data for this Ligand-Target Pair
RET kinase mutant (V804M) (Homo sapiens (Human))	BDBM305367 (US10144734, Example 384 | US10172845, Example 384 ...) Show SMILES CCOc1cc(-c2ccc(nc2)N2CCC(CN(C)C)(CC2)NC(=O)c2ncccc2Cl)c2c(cnn2c1)C#N Show InChI InChI=1S/C29H31ClN8O2/c1-4-40-22-14-23(27-21(15-31)17-34-38(27)18-22)20-7-8-25(33-16-20)37-12-9-29(10-13-37,19-36(2)3)35-28(39)26-24(30)6-5-11-32-26/h5-8,11,14,16-18H,4,9-10,12-13,19H2,1-3H3,(H,35,39)	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	22	n/a	n/a	n/a	n/a	n/a	n/a
Array Biopharma Inc. US Patent					Assay Description The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...				US Patent US10441581 (2019) BindingDB Entry DOI: 10.7270/Q2DZ0BP3
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase receptor Ret (Homo sapiens (Human))	BDBM305367 (US10144734, Example 384 | US10172845, Example 384 ...) Show SMILES CCOc1cc(-c2ccc(nc2)N2CCC(CN(C)C)(CC2)NC(=O)c2ncccc2Cl)c2c(cnn2c1)C#N Show InChI InChI=1S/C29H31ClN8O2/c1-4-40-22-14-23(27-21(15-31)17-34-38(27)18-22)20-7-8-25(33-16-20)37-12-9-29(10-13-37,19-36(2)3)35-28(39)26-24(30)6-5-11-32-26/h5-8,11,14,16-18H,4,9-10,12-13,19H2,1-3H3,(H,35,39)	PDB MMDB KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	5.70	n/a	n/a	n/a	n/a	n/a	n/a
Array Biopharma Inc. US Patent					Assay Description Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...				US Patent US10881652 (2021)
					More data for this Ligand-Target Pair
RET kinase mutant (V804M) (Homo sapiens (Human))	BDBM305367 (US10144734, Example 384 | US10172845, Example 384 ...) Show SMILES CCOc1cc(-c2ccc(nc2)N2CCC(CN(C)C)(CC2)NC(=O)c2ncccc2Cl)c2c(cnn2c1)C#N Show InChI InChI=1S/C29H31ClN8O2/c1-4-40-22-14-23(27-21(15-31)17-34-38(27)18-22)20-7-8-25(33-16-20)37-12-9-29(10-13-37,19-36(2)3)35-28(39)26-24(30)6-5-11-32-26/h5-8,11,14,16-18H,4,9-10,12-13,19H2,1-3H3,(H,35,39)	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
Array Biopharma Inc. US Patent					Assay Description Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...				US Patent US10881652 (2021)
					More data for this Ligand-Target Pair
RET kinase mutant (G810R) (Homo sapiens (Human))	BDBM305367 (US10144734, Example 384 | US10172845, Example 384 ...) Show SMILES CCOc1cc(-c2ccc(nc2)N2CCC(CN(C)C)(CC2)NC(=O)c2ncccc2Cl)c2c(cnn2c1)C#N Show InChI InChI=1S/C29H31ClN8O2/c1-4-40-22-14-23(27-21(15-31)17-34-38(27)18-22)20-7-8-25(33-16-20)37-12-9-29(10-13-37,19-36(2)3)35-28(39)26-24(30)6-5-11-32-26/h5-8,11,14,16-18H,4,9-10,12-13,19H2,1-3H3,(H,35,39)	PDB GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	22	n/a	n/a	n/a	n/a	n/a	n/a
Array BioPharma Inc. US Patent					Assay Description The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...				US Patent US10172845 (2019) BindingDB Entry DOI: 10.7270/Q2M90BR9
					More data for this Ligand-Target Pair